<strong>Fundació</strong> <strong>Institut</strong> <strong>d'Investigació</strong> <strong>en</strong> <strong>Ciències</strong> <strong>de</strong> la Salut Germans Trias i Pujol Planas R. Tratami<strong>en</strong>to antiviral y la cirrosis por el virus <strong>de</strong> la hepatitis B y C. CLIN GASTROENTEROL HEPATOL 2006;6:5‐7 Plauth M, Cabre E, Riggio O, Assis‐Camilo M, Pirlich M, Kondrup J, Fer<strong>en</strong>ci P, Holm E, vom Dahl S, Muller MJ, Nolte W. ESPEN gui<strong>de</strong>lines on <strong>en</strong>teral nutrition: Liver disease. CLIN NUTR 2006; 25(2):285‐294. 2,474 Rodrigo Jover, Pedro Zapater, Antoni Castells, Xavier Llor, Virginia Piñol, Montserrat Andreu, Artemio Payá, Cristina Al<strong>en</strong>da, Rosa M. Xicola, Joaquín Cubiella, Juan D. Morillas, Xavier Bessa, Juan Clof<strong>en</strong>t, Luís Bujanda, Josep M. Reñé, Enrique Quintero. Mismatch repair status in the prediction of b<strong>en</strong>efit from adjuvant fluorouracil chemotherapy in colorectal cancer. A prospective study. GUT 2006 Jun;55(6):848‐55 9,002 Rodriguez‐Moranta F, Castells A, Andreu M, Pinol V, Castellvi‐Bel S, Al<strong>en</strong>da C, Llor X, Xicola RM, Jover R, Paya A, Bessa X, Balaguer F, Cubiella J, Arguello L, Morillas JD, Bujanda L. Clinical performance of original and revised Bethesda gui<strong>de</strong>lines for the id<strong>en</strong>tification of MSH2/MLH1 g<strong>en</strong>e carriers in pati<strong>en</strong>ts with newly diagnosed colorectal cancer: Proposal of a new and simpler set of recomm<strong>en</strong>dations. AM J GASTROENTEROL 2006; 101(5):1104‐1111. 5,608 Sanchez <strong>de</strong> Medina F, Martínez‐Augustin O, Montero T, Suarez MD, Vieites JM, Zarzuelo A, Gassull M.A, Llor X, Suarez A. Effects of sulfasalazine on g<strong>en</strong>e expression profile in trinitrob<strong>en</strong>z<strong>en</strong>esulfonic acid‐induced rat colitis. Submitted for publication. 2006 Sanchez‐Tapias JM, Diago M, Escartin P, Enriquez J, Romero‐Gomez M, Barc<strong>en</strong>a R, Crespo J, Andra<strong>de</strong> R, Martinez‐Bauer E, Perez R, Testillano M, Planas R, Sola R, Garcia‐B<strong>en</strong>goechea M, Garcia‐Samaniego J, Munoz‐Sanchez M, Mor<strong>en</strong>o‐Otero R. Peginterferon‐alfa2a plus ribavirin for 48 versus 72 weeks in pati<strong>en</strong>ts with <strong>de</strong>tectable hepatitis C virus RNA at week 4 of treatm<strong>en</strong>t. Gastro<strong>en</strong>terology 2006; 131(2):451‐460. 12,457 Schrier RW, Gross P, Gheorghia<strong>de</strong> M, Berl T, Verbalis JG, Czerwiec FS, and Orlandi C, for the SALT Investigators (Planas R, Hospital Germans Trias i Pujol). Tolvaptan, a selective oral vasopressin v2‐receptor antagonist, for hyponatremia. NEW ENGL J MED 2006;355:2099‐2112 51,296 Sola R, Alvarez MA, Balleste B, Montoliu S, Rivera M, Miquel M, Cirera I, Morillas RM, Coll S, Planas R. Pàgina 104/177
<strong>Fundació</strong> <strong>Institut</strong> <strong>d'Investigació</strong> <strong>en</strong> <strong>Ciències</strong> <strong>de</strong> la Salut Germans Trias i Pujol Probability of liver cancer and survival in HCV‐related or alcoholic‐<strong>de</strong>comp<strong>en</strong>sated cirrhosis. A study of 377 pati<strong>en</strong>ts. LIVER INT 26(1):62‐72. 2,344 Vives S, Sancho JM, Planas R, Ribera JM. Hepatitis B virus reactivation after cessation of prophylaxis with lamivudine in a pati<strong>en</strong>t with non‐Hodgkin's lymphoma treated with chemotherapy and rituximab. MED CLIN‐BARCELONA 127(1):39‐39. 1,327 Pàgina 105/177